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The NCCLS reference methodology for antifungal susceptibility testing is a new milestone of the evolution of 
medical mycology. The use of t h s  methodology however, is not problem-fi-ee. At present, major limitations 
are a trailing phenomenon with azoles, unreliable detection of resistance to amphotericin B, poor growth of 
some organisms and unpractical procedures for the clinical laboratory. Herein a overview of NCCLS 
guidelines for yeasts and filamentous fungi is presented. Likewise, a review of studies conducted trying to 
overcome the limitations of reference procedures is also included. Several alternative approaches are reviewed 
as alternative meha, inoculum size and incubation time. Modifications of reading procedure and endpoint 
determination are also evaluated. Agar di&sion methods and other methods for susceptibihty testing are cited. 
Finally, we discuss the data on correlation of the in vitro results with the in vivo activity. 
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INTRODUCTION 
Over the years, many studies on in vitro susceptibility of fungi 
have been reported [l]. Their findings presented basic 
hmitations due to interlaboratory variations and the lack of 
correlation between in vitro and in vivo activity [2,3]. However, 
significant progress has been made in t h s  field. Susceptibility 
testing of fungi has recently been standardized by the National 
Committee for Clinical Laboratory Standards (NCCLS), 
Subcommittee on Antifungal Susceptibility Tests. At present, 
these testing methods have only been standardized for Candida 
spp. and C. neofoovmans (document M27-A) [4], and guidelines 
have been proposed for filamentous fungi (document M38-P) 
[5]. The broth dilution tests proposed by the NCCLS feature 
good interlaboratory reproducibdity. This agreement is 
essential to identify organisms unlikely to respond to certain 
antifungal treatments. 
The use of NCCLS methodology is not problem-free. At 
present, the major limitation is the trading phenomenon that 
makes visual determination of azole MICs more difficult, 
because of partial idubition of fungal growth [6,7]. Some 
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stuhes have been conducted to try to overcome the 
limitations. Colorimetric, spectrophotometric and agar d i 6 -  
sion methods have been proposed as modifications of reference 
techniques [3]. The European Committee on Antibiotic 
Susceptibdity Testing (EUCAST) Antifungal Susceptibility 
Testing Subcommittee has performed several studies and is 
conducting a cooperative study to elaborate a method for 
testing the antifungal susceptibihty of fermentative species of 
yeasts. Societies of Clinical Microbiology in several European 
countries are also carrying out collective works [8,9]. The aim 
of all the studies in progress is to develop a practical reference 
methodology for clinical laboratories and a useful tool to 
predct the outcome of therapy with an antifungal agent. 
Here, we present an overview of the NCCLS guidelines for 
yeasts and filamentous fungi, their limitations and some 
modifications of these reference methods. We also review 
the data on the correlation of the in vitro results with in 
vivo activity. 
NCCLS REFERENCE GUIDELINES 
Antifungal susceptibility testing for yeasts 
In 1985, the NCCLS published its first report, in which the 
results of a small collaborative study were presented [lo]. Since 
then, a reproducible reference procedure of antifungal 
susceptibility testing for yeasts has been developed. Several 
cooperative works were conducted to ascertain inoculum 
preparation, inoculum size, choice among several synthetic 
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media, temperature of incubation, duration of incubation, 
end-point determination, reference MIC ranges for quality 
control strains, and breakpoints for available antifungal agents 
[2-4,11,12]. These studies established a broth macrodilution 
reference procedure. A microdilution method as a modifica- 
tion of the macrodilution technique was also developed in 
order to be more practical for the clinical laboratory [13]. 
As a result, the NCCLS document M27-A was published 
[4]. It describes both macrodilution and microdilution 
methods for the antifungal susceptibility testing of Candida 
spp. and C. neoformans. Drug stock preparation, storage and 
dilution techniques are similar to antibacterial testing proce- 
dures with minor modifications. A completely synthetic 
medium is recommended for susceptibility testing. Undefined 
media can give rise to widely varying results [6]. For this 
reason, the synthetic medium RPMI-1640 with 1-glutamine 
buffered to pH 7.0 with 3-[N-morpholino]-propanesulfonic 
acid (MOPS) is advocated by the NCCLS. The pH must be 
strictly controlled. Inoculum preparation follows a spectro- 
photometric method at 530 nm, and tubes or plates are 
inoculated with a final inoculum of 0.5-2.5 x lo3 CFU/mL. 
It has been indicated that higher inocula could increase the 
MICs for the drugs tested, and smaller inocula were associated 
with improvements in interlaboratory reproducibihty [ 14,151. 
Plates or tubes are incubated at 35 "C for 48 h for Candida spp. 
and for 72 h for C. neofrmanr. 
The NCCLS method recommends visual reading but this is 
an important source of variability and inaccuracy [16]. For 
amphotericin B, a fungicidal drug, endpoints are easily defined 
and MIC is the lowest drug concentration that prevents any 
discernible growth compared with the growth control (drug-free 
tube or well). However, fungistatic agents (such as azoles 
ketoconazole, fluconazole, itraconazole and flucytosine) show 
endpoints less clearly defined and introduce sigyficant sub- 
jectivity in reading results [15,17,18]. The document M27-A 
proposes to quanti+ endpoint determination, so MIC is defined 
for the macrodilution procedure as an 80% decrease in turbidity 
as compared with growth control. For broth microdilution, 
MIC is detem7ined according to the 0-4 scale, as follows: 
0 0, optically clear; 
0 1, slightly hazy; 
0 2, prominent decrease in turbidity; 
0 3, slight decrease in turbidity; 
0 4, no reduction in turbimty. 
MIC is defined as the lowest concentration of drugs with 
whch the score is < 2. The quantification of endpoint 
determination and agitation of solutions before reading led to 
more reproducible endpoints determination [19]. Quality 
control procedures and reference strains are also included in 
the document [4]. 
Obviously, a great deal of effort has gone into the 
development of the standardized method for antifungal 
susceptibility testing and the reference techniques are now 
more reliable and reproducible. However, the use of this 
methodology still has some limitations. At present, the main 
problem is the determination of MICs for azoles. This is subject 
to variable interpretation, because of the trailing phenomenon 
caused by partial inhibition offungal growth [18,20]. As already 
stated, visual endpoint determination is a subjective operation, 
particularly with fungistatic agents. Quantification of endpoint 
determination and solution agitation do not settle the issue. For 
some isolates, trailing growth is so significant that the MICs after 
24 h are much lower than after 48 h. Furthermore, a worse 
aspect is that some strains are susceptible to fluconazole and 
itraconazole (MIC < 8 mg/L and MIC 6 0.12 mg/L 
respectively) at 24 h, but resistant at 48 h (2 64 mg/L and > 1 
mg/L) [18]. The relevance of this discordance is unknown but 
evidence suggests that lower MICs correlate most closely with 
the outcome in vioo [21]. MIC determination at 24 h only has 
been proposed to solve the problem [14,16] but numerous 
strains show little or no discernible growth after 24 h of 
incubation [22]. Other authoe have addressed inoculum size, 
reading method or medium p H  [14,15,2>25]. Several studies 
have used spectrophotometric determination of endpoints to 
eliminate such subjective interpretation [19,20,24]. Marr et al. 
reported that adjustment in the pH ofmedia to acidic conditions 
@H 4.5) can reduce trailing in C. albicans without aEecting the 
MICs of fluconazole [25]. More comprehensive studies are 
needed to resolve the phenomenon of trailing and to ascertain 
its effects on clinical response. 
A second major limitation is poor growth of C. neoformans 
and other nonfermentative yeasts with media recommended 
by the NCCLS 126,271. Therefore, several authors have 
advised a number of different ways of overcoming the 
problem. Media such as buffered yeast nitrogen base (BYNB) 
[26] or RPMI supplemented with 2% glucose have been 
employed [28]. Better rates of growth were obtained with 
BYNB, and MICs were not falsely elevated [29]. Odds et al. 
demonstrated that oxygen is a limiting factor for C. neDfomans 
growth in liquid media [30] and cultivation under constant 
agitation has been recommended [28]. 
The other major limitation of the NCCLS methods 
described for antifungal susceptibility testing is reliable 
detection of resistance to amphotericin B [4]. RPMI medium 
yields a range of MICs that span only three or four twofold 
serial dutions [7]. This short range precludes reliable 
discrimination between susceptible and resistant isolates. 
Current reports suggest that testing with Antibiotic Medium 
3 (AM3) instead of RPMI permits us to enhance the ability to 
detect it [31]. However, the reproducibility of this method is 
still under study, owing to lot-to-lot variability of AM3 [32]. 
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Despite its limitations, the NCCLS reference methodology 
for antifungal susceptibility testing is a new d e s t o n e  in the 
evolution of medical mycology. It is possible, even likely, that 
new antifungal agents require modified methods or that new 
assays will show a better correlation between in vitro and in viuo 
susceptibility results and patients' outcomes. However, at 
present, the NCCLS procedure is the most reliable and 
reproducible methodology, and any progress in this field must 
take it into account. 
Antifungal susceptibility testing for filamentous fungi 
The document M38-P describes a method for testing the 
susceptibility to antifungal agents of filamentous fungi 
(moulds), including Aspergillus spp. Fusarium spp., Rhizopus 
arrhizus, Pseudallescheria boydii and Sporothrix schenckii [5]. These 
species are conidium-forming moulds. A working group was 
formed and charged with the responsibility of carrying out 
studles to collect data and to propose a way to perform 
susceptibility testing of those fungal species. As a result of two 
collaborative works, the document was published [33,34]. 
The M38-P methodology adopts some of the steps in yeast 
testing [4]. The guidelines include both macro- and micro- 
dilution methods [5]. Drug stock preparation and dilution 
procedures are similar to the yeast techniques. The synthetic 
medium RPMI-1640 is also advocated. Fungi are grown on 
potato agar slants at 35 "C for 7 days. Inocula are prepared by a 
spectrophotometric procedure at 530 nm, and tubes or plates 
are inoculated with a final suspension of approximately 0.4- 
5 x lo4 CFU/mL [7]. It has been indicated that inoculum 
preparation as specified here provides the most reproducible 
MIC data. Table 1 displays the optical density range at 530 nm 
correlated with inoculum size for filamentous fungi included 
in document M38-P. Plates or tubes are incubated at 35 "C for 
72 h and examined daily. Readings are obtained with the aid 
of a mirror and endpoint determination adopts criteria 
developed for antifungal testing of yeasts [3]. Interpretative 
breakpoints are not avadable but some degree of correlation 
has been demonstrated between in uitro test results and 
response to treatment in animal models p,35]. 
The limitations in standardized susceptibility testing for 
yeasts are considerable, and developing a reference methodol- 
ogy for filamentous fungi represents a major challenge with 
unsolved problems. First, the incubation period for obtaining 
the inoculum lasts several days, which is a major limitation for 
the clinical susceptibdity testing of moulds [2,3]. In addition, 
the document M38-P describes guidelines for conidmm- 
forming moulds, and conima are small spheres that are easily 
quantifiable [5]. However, obtaining conidial suspensions is 
not possible when the moulds present germinate to hyphal 
forms. Preparation of hyphal or germinated sporangiospores 
suspensions is difficult and limited data suggest that ths  is an 
important source of discrepancies [36,37]. Collaborative 
studies have not been conducted for nonconidium-forming 
moulds and published results are less consistent in reliabihty 
than data obtained with species included in the proposed 
reference method [2,3,38]. 
Finally, as mentioned in relation to yeasts, visual reading 
introduces subjective interpretations of susceptibility results. 
Using the conventional criterion of complete growth inhlbi- 
tion inaccuracy is minimized, but the NCCLS recommends 
quantification of endpoint determination in order to avoid the 
trailing phenomenon with fungistatic agents [5,33]. Data 
recently reported have revealed that 100% inhibition instead of 
50% can be the optimal testing condition to improve 
reproducibility with azoles and even to detect potential azole 
resistance in moulds. These refined gmdelines and results 
obtained by the evaluation of other species of fun@ will be 
included in a new NCCLS document (M38-T) [7]. 
MODIFICATIONS OF REFERENCE METHODS 
The reference method already mentioned is not the best 
technique for testing all organisms or the most convenient 
G a b l e  1 Optical density ranges and inoculum 
sizes for filamentous fungi included in M38-P Species No. Optical density lnoculurn size 
observations range mean ( x 10' CFU/mL) dncumsnta 
Aspergillus flavus 105 0.09-0.1 1 1.6 
Aspergillus fumigatus 104 0.094.1 1 2.7 
Fusarium oxysporum 105 0.1 5-0.1 7 3.0 
Fusarium soiani 103 0.1 5-0.1 7 1.8 
Pseudallescheris boydii 99 0.1 5-0.1 7 1 .o 
Rhizopus arrhizus 99 0.1 5-0.1 7 1.3 
Sporothrix schenckii NAb 0.09-0.1 1 2.4 
Paecilomyces variotii NA 0.11-0.17 1 .1 
(ATCC 22315) 
aData are from ref. [3]. 
bNA. not applicable. 
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procedure for routine use in clinical laboratories. As a 
consequence, a number of modifications of the NCCLS 
methodology have been proposed. Several alternative ap- 
proaches have been evaluated, including techniques used for 
antibacterial susceptibility testing. In particular, microdilution 
procedures are employed in these modifications. 
Alternative media, inoculum size and incubation time 
The document M27-A includes some alternative media for 
special circumstances but indicates that the utility of these 
modifications remains to be established. These alternative 
medla are AM3, BYNB and RPMI supplemented with 2% 
glucose [4]. Alternative media have been accepted, because of 
limitations of the reference techmque [2,6]. 
The M27 methodology does not permit consistent detec- 
tion of isolates resistant to amphotericin B. Several works 
suggest that testing with AM3 supplemented with 2% glucose 
permits more reliable detection of these isolates, but AM3 is 
not standardized and substantial lot-to-lot variabibty has been 
observed [31,32]. Variabihty is a basic limitation for 
reproducibility. Thus, other defined synthetic medla could 
represent alternatives to detect resistance to amphotericin B. 
Preliminary data suggest that Iso-Sensitest could distinguish 
susceptible and resistant isolates. Iso-Sensitest is a semidefined 
medium for antimicrobial susceptibility testing in which 
undefined components are kept to a minimal level [MI. 
Ghannoum et ul. reported that the use of BYNB media may 
enhance the growth of C. Neofomuns [26]. This yeast exhibits 
poor growth with RPMI-1640. Thus, BYNB and an inoculum 
of 10" CFU/mL have been defined as the optimal method for 
determining the susceptibility of C. neoformans [29]. Inoculum 
effects in determining MICs of antifungal agents were not 
observed and improvements in the clinical relevance of 
antihngal MICs have been found. Other authors have 
recommended the cultivation of the microdilution trays under 
constant agitation and an inoculum size of lo5 CFU/mL at 35 
"C [28]. Some reports have indicated that the maximum rate of 
growth of C. neojbmw is observed at 30 "C [40]. These reports 
demonstrate the need for a more reliable and reproducible new 
reference methodology of antihngal susceptibility testing of C. 
neofotvnans and other nodermentative yeasts. 
Another modification is the supplementation of RPMI with 
2% glucose for all organisms [22]. It has been suggested that 
glucose supplementation may simplifi endpoint determina- 
tion, because of higher turbidity of the growth control [14,16]. 
In addition, numerous strains show no discernible growth after 
24 h of incubation when the NCCLS reference method is 
employed, and FWMI-2% glucose has the advantage of 
shortening the incubation time [41]. Growth increases when 
hgher inoculum sizes are employed (lo4 or lo5 CFU/mL) 
and MICs are not falsely elevated [42,43]. Thus, the 
Antihngal Susceptibility Testing Subcommittee of EUCAST 
is c q n g  out a collaborative study comparing M27-A 
procedures with a new method for the determination of 
MIC by broth dilution of fermentative species of yeasts. This 
methodology includes RPMI-2% glucose and an inoculum 
size of lo5 CFU/mL. Figure 1 and Table 2 display preliminary 
data of the EUCAST cooperative work. The MICs for quality 
control strains are similar to the NCCLS reference values, and 
0 4 8 12.18 20 24 28 92 38 40 44 48 
IncubanonamelnhQur 
Fig 1 Growth kinetics of 24 clinical isolates of Candida spp. (six 
different species). Comparison between NCCLS reference methodol- 
ogy (RPMI and inoculation of lo3 CFU/mL) and new method, 
including 2% glucose and lo5 CFU/mL. OD, optical density. 
Table 2 In vitro data on qulaity 
control strains Candida krusei Organism Antifungal NCCLS reference 
ATCC 6258 and Candida agent MIC range (mg/L) 
parapsilosis ATTC 2201 9 
Candida krusei Amphotericin 6 0.52.0 
ATCC 6258 Fluconazole 16-64 
ltraconazole 0.1 2-0.5 
Ketoconazole 0.1245 
Flucvtosine 4.0-1 6 
RPMI-2% glucose and 
lo5 CFU/mL MIC range (rng/L) 
0.5-1 .O 
0.1 2-0.5 
0.0601 500.25 
4.0-8.0 
16-32 
Candida parapsilosis Amphotericin B 0.25-1 .O 0.25-1 .O 
ATCC 2201 9 Fluconazole 2.0-8.0 1.0-4.0 
ltraconazole 0.06-0.25 0.1 2-0.25 
Ketoconazole 0.06-0.25 0.06-0.25 
Flucytosine 0.1 2-0.5 0.1 2-0.5 
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the growth kinetics show that 24 h is an optimal incubation 
period for MIC determination. These data could confirm that 
the M27-A technique modified with 2% glucose and higher 
inocula offers the advantages of reducing the incubation time 
and simplifying endpoint determination, without sigmficant 
inoculum effects in determining MICs. 
Alternative mema are not described in the document M38- 
P for moulds. However, it has been suggested that inoculum 
preparation by a spectrophotometric procedure can be a 
source of inaccuracy, owing to the color and size of spores, 
which are species dependent [36-381. Therefore, individual 
features of strains could have an influence on the optical 
density of inoculum suspensions. Reports have indicated that 
inoculum size should be adjusted by using a hemacytometer 
cell-counting chamber [44,45]. Inoculum quantification has to 
be performed by plating serial dilutions of suspensions. Other 
authors have reported that the hemacytometer count is less 
consistent in between-laboratory tests than the spectrophoto- 
metric procedure [6]. RPMI-2% glucose and a higher 
inoculum size have also been employed for antifungal 
susceptibility testing of moulds, being an acceptable means 
of evaluating the in vitro activity of antifungal agents against 
these organisms [46,47]. 
Modifications of reading procedure and endpoint determination 
An alternative to the reference method of visually gradmg 
turbidity is the determination of endpoints with automated 
spectrophotometric methods. Microtiter trays and automated 
reading allow the determination of endpoints at hfferent levels 
of growth inhibition [14]. Several studies have assessed various 
levels of growth inhibition, in comparison with that of the 
drug-free control well [15,19,20,24]. Levels of 50% with the 
azoles and 80-90% with amphotericin B have provided the 
most accurate values [3]. Excellent agreement has been 
observed between the results of the spectrophotometric and 
standard methods, but most studies tested exclusively C. 
albicans. Therefore, the collaborative work of the Antifungal 
Susceptibility Testing Subcommittee of EUCAST is assessing 
both automated and visual methods with several yeasts species. 
A novel modification is the use of a colorimetric oxidation- 
reduction indicator [2]. This technique is used in bacterial 
reference methods and allows the determination of viable cells. 
Several indicators have been employed, but only the use of 
Alamar Blue (Alamar Biosciences, Inc., Sacramento, USA) has 
been analyzed in depth. Alamar Blue is an indicator that 
changes color from blue to red when reduced in the presence 
of microbial growth. It has been incorporated into the 
Sensititre Yeast One Antifungal Panel (Accumed Intema- 
tional, Ohio, USA), which is a disposable microdilution tray, 
and numerous studies have been carried out [48,49]. 
The indicator aids in the determimoon of visual MIC 
endpoints and could be a more convenient procedure than the 
standard method for use in the clinical laboratory. The agreement 
of colorimetric microdilution MICs with the NCCLS reference 
procedures has been acceptable, with the exception of some 
species (C. albicans for azoles and flucytosine or C. neofmns  for 
amphotericin B) [49]. For filamentous fungi, colorimetric MICs 
have also been determined and excellent agreement has been 
observed. Moreover, colorimetric MICs afier 48-72 h of 
incubation with an inoculum size of lo4 CFU/mL have been 
defined as optimal testing conditions and proposed as guidelines 
for a reference method for testing moulds [34]. 
Agar diffusion and other methods for susceptibility testing 
Disk-diffusion tests and E-test strips (As Biodisk, Solna, 
Sweden) have been employed for antifungal susceptibdity 
testing. These procedures are straightforward, economical to 
perform and offer a practical method for the clinical laboratory 
[2,3]. However, agreement with reference methods is species 
and medium dependent. Disk-diffusion tests, such as Neo- 
sensitabs (Rosco Diagnostica, Taastrup, Denmark), have been 
employed in several studies [43,50,51]. Most of these 
exclusively evaluated disks of fluconazole and Candida spp. 
Work has also been conducted to assess disk-ditrusion 
susceptibility testing of dermatophytes [52]. E-test strips have 
been more extensively analyzed [2,3,53,54]. This appears to be 
a suitable alternative procedure for testing the susceptibility of 
yeasts and moulds to azoles and amphotericin B. However, 
poor agreement with the reference methods has been reported 
for Candida glabrata, C. tropicalis, C. neofomzans and some 
filamentous fungi. At present, the role of agar diffusion 
methods is not clearly defined, although it may have promise. 
Other methodologes for testing the susceptibihty of yeasts 
and moulds involve either direct determination of cell mass or 
cell viability by fluorescence, or indirect determination of cell 
mass by calorimetry, analysis of ATP production or radiometry 
[55-571. Expensive equipment is required, some methods are 
very laborious and some involve subjective interpretation. 
Agreement with reference procedures is not evaluated in some 
of published reports. More comprehensive studies are needed 
to determine the usefulness of these methodologies. 
Finally, several novel commercial systems for antifungal 
susceptibility testing have been developed. They are based on 
microtitration or colorimetric procedures. The usefulness of 
these techniques remains undetermined [58,59]. 
CLINICAL CORRELATION AND RESISTANCE DETECTION 
In vitro susceptibility testing should reliably predict the in uivo 
response to therapy in human infections. However, numerous 
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factors af3ect the clinical response to antifungal therapy, 
regardless of the MIC endpoint for the infecting organism. 
Host factors may have more effect on the infection than 
susceptibility to antifungal agents, and a low MIC does not 
necessarily predict clinical success [7]. However, an in vitro 
susceptibility test may be able to identify organisms unlikely to 
respond to certain antimicrobial agents. 
Evidence of a correlation between clinical outcome and 
antifungal susceptibility testing has been limited untd recently. 
Good interlaboratory reproducibility of the NCCLS reference 
guidelines for yeasts has led to the establishment of 
interpretative breakpoints for fluconazole, itraconazole and 
flucytosine, but for Cundidu species only (Table 3) [4]. 
Breakpoints for fluconazole were established following 
correlation between azole MICs and the clinical response of 
patients with AIDS, and oropharyngeal candidosis and non- 
neutropenic patients with candidemia or visceral infection [l- 
3,7]. Itraconazole breakpoints were defined with clinical data 
on oropharyngeal candidosis only [12]. Breakpoints for 
flucytosine were established on the basis of historical data 
and the pharmacokinetics of the drug, because of the shortage 
of available in vitvo results obtained by the NCCLS methods 
[4]. Breakpoints for amphotericin B and other antifungal 
agents have not been proposed. Recent reports point out that 
either E-test MICs or minimal hngicidal concentrations are 
better predictors of clinical failure to amphotericin B therapy 
than are the reference NCCLS procedures [7,60]. However, 
these methodologes have not been standardized. 
For the f3amentous fmgi, interpretative breakpoints are not 
available. Historically, it has been suggested that an amphotericin 
B MIC > 1 mg/L could correlate with a lack of response of 
treatment in experimental mould infections [1,2,7]. However, 
these data have been reviewed recently. An NCCLS study using 
the M38-P methodology has indicated some degree of 
correlation between in oitm tests and response to treatment in 
animal models. Lack of response was observed with R. urrhizus 
and Aspqillus spp. isolates for whch MICs of amphotericin B 
were 2 2  mg/L and MICs of itraconazole >1 mg/L [35]. 
However, other authors report a lack of correlation of in oitro 
amphotericin B susceptibihty testing with outcome in a murine 
model of Aspergdlus infection [61]. Some data are also available 
from clinical stumes. A certain correlation was observed for 29 
patients with hematological diseases and Aspgillus spp. infection. 
Mortality was sigdcantly associated with MICs of amphotericin 
B 2 2  mg/L. The relationship was more sigdcant for patients 
infected by Asperrgillus terreus [62]. In addition, Denning et al. 
have identified strains of A. &migatus resistant to itraconazole. 
These strains showed MICs of itraconazole 2 16 mg/L and were 
isolated from patients who had fsjled itraconazole treatment [63]. 
The results were confirmed in a neutropenic mouse model of 
invasive aspergdlosis [64]. 
It must be emphasized that breakpoints are tentative and 
more data are needed. The clinical usefulness of in vitro tests 
must be established in other clinical settings and for other 
organism-drug combinations. More reliable detection of 
resistance to amphotericin B is clearly needed. However, the 
currently available in oitro tests can detect both intrinsic and 
primary resistance (moulds to fluconazole, Trichosporon spp. to 
amphotericin B, Cundidu knrsei to fluconazole and others). The 
reference methodology is also able to detect multiresistant 
organisms (Scedospon'um prol$cam and other species of moulds) 
and, moreover, breakpoints for fluconazole and itraconazole 
have clinical relevance in oropharyngeal candidal infection in 
HIV-infected patients [1,7,65,66]. 
CONCLUSIONS 
Considerable progress has been achieved in antihngal 
susceptibility testing. A reproducible reference methodology 
has been developed by the NCCLS. These procedures are not 
problem-free, but are essential to identify organisms unlikely 
to respond to certain antifungal treatments. At present, major 
limitations are the trailing phenomenon with azoles, unreliable 
resistance to amphotericin B detection, poor growth of some 
organisms and impractical procedures for the clinical labora- 
tory. Several collaborative studies are in progress with the 
intention to overcome the limitations and to develop a 
practical reference methodology and a useful clinical tool. 
Good interlaboratory reproducibility of the the NCCLS 
reference guidelines for yeasts has led to the establishment of 
interpretative breakpoints for fluconazole, itraconazole and 
flucytosine. Resistant breakpoints for fluconazole and itraco- 
nazole have been well documented, with treatment failure 
d y  in HIV patients with oropharyngeal candidosis. 
Table 3 Interpretative guidelines for 
susceptibility testing in vitro of Candida Ant i fungal  Susceptible Susceptible-dose In termediate Resistant 
species agent  dependent 
Fluconazole 6 8  16-32 > 64 
Flucytosine <4 8-1 6 > 32 
- 
- ltraconazole G0.125 0.25-0.5 2 1  
- 
Breakpoints in mg/rnL. Data are from ref. [4]. 
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Correlations in other clinical settings are unknown. Further 
studies are needed to evaluate the clinical usefulness of the in 
vitro tests for other species of yeasts and filamentous fun@. 
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